We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
Atlas Arteria is an infrastructure operations business based in Australia. Atlas Arteria shares (ALX) are listed on the Australian Securities Exchange (ASX) and all prices are in Australian dollars. Atlas Arteria has a trailing 12-month revenue of around $100.7 million. If you're looking to buy shares, check out the steps below.
Our top pick for
US stocks
Our top pick for
Best Overall Broker
Our top pick for
Best low-cost broker
| 52-week range | $5.5075 - $7.03 |
|---|---|
| 50-day moving average | $6.6592 |
| 200-day moving average | $6.5778 |
| Target price | $6.85 |
| PE ratio | 35.7592 |
| Dividend yield | $0 (5.56%) |
| Earnings per share (TTM) | $0.191 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. However, this is not a recommendation. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Historical closes compared with the last close of A$6.85
| 1 week (2022-05-09) | 0.29% |
|---|---|
| 1 month (2022-04-14) | 3.16% |
| 3 months (2022-02-16) | 2.24% |
| 6 months (2021-11-16) | 5.55% |
| 1 year (2021-05-14) | 10.13% |
|---|---|
| 2 years (2020-05-15) | 14.93% |
| 3 years (2019-05-16) | -3.90% |
| 5 years (2017-05-16) | 24.58% |
Valuing Atlas Arteria stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Atlas Arteria's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Atlas Arteria's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 36x. In other words, Atlas Arteria shares trade at around 36x recent earnings.
That's relatively high compared to, say, the P/E ratio for the ASX over the 12 months to December 2019 (32.14). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Atlas Arteria's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $36.7 million (£0.0 million).
The EBITDA is a measure of a Atlas Arteria's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $100.7 million |
|---|---|
| Gross profit TTM | $368.7 million |
| Return on assets TTM | -0.29% |
| Return on equity TTM | 4.59% |
| Profit margin | 182.02% |
| Book value | 3.647 |
| Market capitalisation | $6.6 billion |
TTM: trailing 12 months
Dividend payout ratio: 2% of net profits
Recently Atlas Arteria has paid out, on average, around 2% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 5.56% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Atlas Arteria shareholders could enjoy a 5.56% return on their shares, in the form of dividend payments. In Atlas Arteria's case, that would currently equate to about A$0 per share.
While Atlas Arteria's payout ratio might seem low, this can signify that Atlas Arteria is investing more in its future growth.
The latest dividend was paid out to all shareholders who bought their shares by 21 March 2022 (the "ex-dividend date").
Over the last 12 months, Atlas Arteria's shares have ranged in value from as little as $5.5075 up to $7.03. A popular way to gauge a stock's volatility is its "beta".
Beta measures a share's volatility in relation to the market. The market (AU average) beta is 1, while Atlas Arteria's is 0.8958. This would suggest that Atlas Arteria's shares are less volatile than average (for this exchange).
Atlas Arteria Limited owns, develops, and operates toll roads. It holds a 13.4% interest in 22-kilometer toll road investors partnership II (TRIP II), the concessionaire for Dulles Greenway toll road located in Virginia, the United States. The company was formerly known as Macquarie Atlas Roads Limited and changed its name to Atlas Arteria Limited in May 2018. Atlas Arteria Limited was incorporated in 2009 and is based in Melbourne, Australia.
Everything we know about the Regener8 Resources IPO, plus information on how to buy in.
While crypto ETFs remain a relatively new concept, here is how you can invest in one of the first physically back Bitcoin ETFs.
Here is your how to guide on buying the first Ethereum backed ETF in Australia.
Everything we know about the Southern Palladium Limited IPO, plus information on how to buy in.
Everything we know about the Coolabah Metals IPO, plus information on how to buy in.
Steps to owning and managing Firetail Resources shares.
Considering buying a hedged or unhedged ETF? Here is what you need to know prior to investing.
Steps to owning and managing Gran Tierra Energy shares from Australia.
Copy trading is a strategy that allows you to follow other traders. This guide will help you understand what it is and if its right for you.
